DECAMP-1: Diagnosis and Surveillance of Indeterminate Pulmonary Nodules
- Conditions
- Lung Cancer
- Interventions
- Other: Biosample and Imaging Collection
- Registration Number
- NCT01785342
- Lead Sponsor
- Boston University
- Brief Summary
The goal is to improve the efficiency of the diagnostic follow-up of patients with indeterminate pulmonary nodules by determining whether biomarkers for lung cancer diagnosis that are measured in minimally invasive biospecimens are able to distinguish malignant from benign pulmonary nodules that are incidentally detected in high-risk smokers.
- Detailed Description
The Detection of Early lung Cancer Among Military Personnel (DECAMP) consortium is a multidisciplinary and translational research program that includes 7 Veterans Administration Hospitals (VAH), the 4 designated Military Treatment Facilities (MTF) and 4 academic hospitals as clinical study sites, several molecular biomarker laboratories, along with Biostatics, Bioinformatics, Pathology and Biorepository cores. The DECAMP Coordinating Center will facilitate rapid selection, design and execution of clinical studies within this multi-institutional consortium. The goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. The diagnostic performance of four previously established lung cancer biomarkers in this cohort will be validated; 1) a gene-expression biomarker measured in bronchial airway brushings; 2) a proteomic signatures measured in bronchial airway biopsies; 3) a proteomic signature measured in serum; and 4) a signature of serum cytokines. The added value of the molecular markers to clinical and imaging markers routinely used in the diagnostic work up of these patients and develop an integrated model (i.e. clinical, imaging \& molecular markers) that results in the most robust diagnostic predictor will be evaluated.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 489
- 45 years of age or older;
- Initial diagnosis of indeterminate pulmonary nodule (0.7-3.0 cm);
- Smoking status: Current or former smoker with โฅ 20 pack years (pack years = number of packs per day X number of years smoked)
- Willing to undergo fiberoptic bronchoscopy;
- Able to tolerate all biospecimen collection as required by protocol;
- Able to comply with standard of care follow up visits including clinical exams, diagnostic work-ups, and imaging for a minimum of two years;
- Able to fill out Patient Lung History questionnaire;
- Willing and able to provide a written informed consent.
- History or previous diagnosis of lung cancer;
- Diagnosis of pure ground glass opacities on chest CT;
- Contraindications to nasal brushing or fiberoptic bronchoscopy including ulcerative nasal disease, hemodynamic instability, severe obstructive airway disease, unstable cardiac or pulmonary disease; inability to protect airway or altered level of consciousness;
- Allergies to any local anesthetic that may be used to obtain biosamples in the study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Indeterminate Pulmonary Nodule Biosample and Imaging Collection The goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. Biosample and imaging collection will be done.
- Primary Outcome Measures
Name Time Method Lung Cancer 2 years Subjects will be identified as Lung Cancer or no Lung Cancer (through diagnosis) within the 2 year followup period.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (15)
Walter Reed National Military Medical Center
๐บ๐ธBethesda, Maryland, United States
Health Research Inc. Roswell Park Division
๐บ๐ธBuffalo, New York, United States
Regents of the University of California LA (Los Angeles VA Healthcare System)
๐บ๐ธLos Angeles, California, United States
Trustees of University of Pennsylvania (Philadelphia VA Medical Center)
๐บ๐ธPhiladelphia, Pennsylvania, United States
University of California Los Angeles Medical Center
๐บ๐ธLos Angeles, California, United States
Naval Medical Center San Diego
๐บ๐ธSan Diego, California, United States
Naval Medical Center Portsmouth
๐บ๐ธPortsmouth, Virginia, United States
Denver Research Institute
๐บ๐ธDenver, Colorado, United States
Boston University Medical Center
๐บ๐ธBoston, Massachusetts, United States
Middle Tennessee Research Institute (Vanderbilt University)
๐บ๐ธNashville, Tennessee, United States
San Antonio Military Medical Center
๐บ๐ธSan Antonio, Texas, United States
Boston VA Research Institute, Inc
๐บ๐ธBoston, Massachusetts, United States
Veterans Research Foundation of Pittsburgh
๐บ๐ธPittsburgh, Pennsylvania, United States
University of Pennsylvania
๐บ๐ธPhiladelphia, Pennsylvania, United States
Dallas VA Research Corporation
๐บ๐ธDallas, Texas, United States